SUSAN WEEKS: Open Payments
NPI 1801868617 · MARTINSVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,168 in 64 payments from 18 companies in 2025. Trend: 2023 $1,045 · 2024 $1,326 · 2025 $1,168
Food & beverage: $1,168
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $230 |
| ABBVIE INC. | 14 | $218 |
| Lundbeck LLC | 4 | $84 |
| Abbott Laboratories | 4 | $78 |
| AstraZeneca Pharmaceuticals LP | 5 | $76 |
| PFIZER INC. | 3 | $59 |
| Amgen Inc. | 4 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 3 | $48 |
| Astellas Pharma US Inc | 2 | $41 |
Products named: QULIPTA, Ozempic, VRAYLAR, VYEPTI, FREESTYLE LIBRE 3, OTEZLA, CAPLYTA, SPRAVATO.
Industry payments across VA — which companies pay providers there.
